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Abstract—Glioblastoma is a highly invasive brain tumor, whose
cells infiltrate surrounding normal brain tissue beyond the lesion
outlines visible in the current medical scans. These infiltrative
cells are treated mainly by radiotherapy. Existing radiotherapy
plans for brain tumors derive from population studies and
scarcely account for patient-specific conditions. Here we provide
a Bayesian machine learning framework for the rational design of
improved, personalized radiotherapy plans using mathematical
modeling and patient multimodal medical scans. Our method, for
the first time, integrates complementary information from high
resolution MRI scans and highly specific FET-PET metabolic
maps to infer tumor cell density in glioblastoma patients. The
Bayesian framework quantifies imaging and modeling uncer-
tainties and predicts patient-specific tumor cell density with
credible intervals. The proposed methodology relies only on
data acquired at a single time point and thus is applicable to
standard clinical settings. An initial clinical population study
shows that the radiotherapy plans generated from the inferred
tumor cell infiltration maps spare more healthy tissue thereby
reducing radiation toxicity while yielding comparable accuracy
with standard radiotherapy protocols. Moreover, the inferred
regions of high tumor cell densities coincide with the tumor
radioresistant areas, providing guidance for personalized dose-
escalation. The proposed integration of multimodal scans and
mathematical modeling provides a robust, non-invasive tool to
assist personalized radiotherapy design.
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I. INTRODUCTION
GLIOBLASTOMA (GBM) is the most aggressive andmost common type of primary brain tumor, with a me-
dian survival of only 15 months despite intensive treatment [1].
The standard treatment consists of immediate tumor resection,
followed by combined radio- and chemotherapy targeting the
residual tumor. All treatment procedures are guided by mag-
netic resonance imaging (MRI). In contrast to most tumors,
GBM infiltrates surrounding tissue, instead of forming a tumor
with a well-defined boundary. The central tumor, which is
visible on medical scans, is commonly resected. However,
the distribution of the infiltrating residual tumor cells in the
nearby healthy-appearing tissue, which are likely to contribute
to tumor recurrence, is not known.
Current radiotherapy (RT) planning handles these uncertainties
in a rather rudimentary fashion. Guided by population-level
studies, standard-of-care RT plans uniformly irradiate the
volume of the visible tumor extended by a uniform margin
[1]–[3], which is referred as the clinical target volume (CTV).
However, the extent of this margin varies by few centimeters
even across the official RT guidelines [4]. Moreover, GBM
infiltration is anisotropic and thus a uniform margin very likely
does not provide an optimal dose distribution. In addition,
GBM invasiveness is highly patient-specific, and thus not all
patients benefit equally from the same margin, which impairs
comparison and advancement of RT protocols.
Despite treatment almost all GBMs recur [5]. Biopsies [6] and
post-mortem studies [7] show that tumor cells can invade be-
yond the CTV, which reduces RT efficiency, and is a possible
cause of recurrence. At the same time radioresistance of tumor
cells inside the CTV can also reduce RT efficiency. Radioresis-
tance tends to occur in regions with complex microenviroment
and hypoxia [8], both of which are commonly encountered in
areas of high tumor cellularity. To address tumor radioresis-
tance, several studies have suggested local dose-escalations
[8]–[10]. In these approaches, a boosted dose is delivered into
a single or multiple co-centered regions defined by adding
uniform margins to the tumor outlines visible in MRI scans
[11]. The Radiation Therapy Oncology Group (RTOG) phase-
I-trial [10] showed an increase in median survival of 8 months
with dose-escalation. However, no benefit in progression-
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2free survival was observed, indicating a complex relationship
between true progression of the underlying disease and the
tumor extent visible in MRI scans.
Alternatively, positron emission tomography (PET) scans,
which map tumor metabolic activities targeted by specific
tracers, can be used to identify radioresistant regions. A
promising tracer used in GBM imaging is 18F-fluoro-ethyl-
tyrosine (FET) [12], whose uptake values have been shown
to be proportional to tumor cell density, although the con-
stant of proportionality is unknown and patient-specific [13],
[14]. A prospective phase-II-study [5] demonstrated that dose-
escalation based on FET-PET enhancement delineates the
tumor structure better than uniform margins, thus leading to
lower radiation toxicity. Still, FET-PET based dose-escalation
did not increase progression-free survival. One possible expla-
nation is that PET enhances mainly the tumor core, which is
usually resected, while the PET uptake values in the remaining
tumor periphery coincide with the baseline signal from the
healthy tissue. This, together with a rather low resolution of
PET scans, limits their ability to fully target radioresistant
tumor residuals. This is also consistent with our results.
Standard RT plans can be improved by incorporating in-
formation from computational tumor models. These models,
calibrated against patient medical scans, provide estimates
of tumor infiltration that extend the information available
in medical images and can guide personalized RT design.
Despite extensive development of tumor growth models [15]–
[20] and calibration strategies [21]–[28], their translation into
clinical practice remains very limited. We postulate that there
are (at least) three translational weakness: 1) Most model
calibrations rely on data not commonly available in clinical
practice. For example, in [22]–[28] medical scans with visible
tumor progression from at least two time points are used for
the model calibration. However, for GBM patients only scans
acquired at single preoperative time point are available. 2)
Models are based on simplified assumptions motivated by
in-vitro studies. For instance, it is frequently assumed that
the tumor cell density is constant along the tumor borders
visible on MRI scans (e.g., [21]–[27]). However, the tumor
cell density varies significantly along the visible lesion borders
due to anatomical restrictions and anisotropic tumor growth.
3) Even if advanced calibration techniques as in [28] are used,
it is not clear how robust the model predictions are and what
benefits they offer over the standard treatment protocols.
Here, we address these translational issues and provide clin-
ically relevant patient-specific tumor predictions to improve
personalized RT design. We present a Bayesian machine
learning framework to calibrate tumor growth models from
multimodal medical scans. We show that an integration of in-
formation from complementary structural MRI and functional
FET-PET metabolic maps enables the robust inference of the
tumor cell densities from scans acquired at single time point.
To the best of our knowledge, this is the first study making
joint use of FET-PET and MRI scans for the patient-specific
calibration of a tumor growth model. Our Bayesian approach
infers modeling and imaging parameters under uncertainties
arising from measurement and modeling errors. We propagate
these uncertainties through the computational tumor model
to obtain robust estimates of the tumor cell density together
with credible intervals that can be used for personalized RT
design. The patient-specific tumor estimates offer an advantage
in determining margins of CTV as well as regions for dose-
escalation. A clinical study is used to assess benefits of the
personalized RT design over standard treatment protocols.
In the remainder of the paper, Section II introduces the
Bayesian framework for model calibration, including the tu-
mor growth and imaging models. The results are presented in
Section III where the framework is applied to synthetic and
clinical data, followed by a personalized RT study. Conclu-
sions are presented in Section IV. Additional technical details
are given in the Supplementary Materials (SM) available in
http://ieeexplore.ieee.org.
II. BAYESIAN MODEL CALIBRATION
The Bayesian framework we develop combines a determin-
istic model Mu for tumor growth with a stochastic imaging
model MI relating model predictions with tumor observations
available from patient medical scans. Bayes theorem is used
to estimate the probability distribution of the unknown pa-
rameters of both models, accounting for modeling and mea-
surement uncertainties. Identified parametric uncertainties are
propagated to obtain robust patient-specific tumor predictions.
An overview of the framework is given in Fig. 1.
A. Tumor growth model
Many tumor growth models are based on the Fisher-
Kolmogrov (FK) equation [23], which captures the main tumor
behaviour: proliferation and infiltration. We use FK equation
to describe the tumor model Mu. The equation is solved in a
patient-specific brain anatomy reconstructed from MRI scans,
where each voxel corresponds to one simulation grid point. Let
Ω ∈ R3 be the brain anatomy consisting of white and grey
matter and ui(t) ∈ [0, 1] be normalized tumor cell density
at time t and voxel i at location (ix, iy, iz) ∈ Ω, where
i = {1, · · · , N} is index across all voxels. The dynamics of
the tumor cell density u ··= {ui(t)}Ni=1 is modeled as:
∂u
∂t
= ∇ · (D∇u) + ρu (1− u) in Ω, (1)
∇u · ~n = 0 in ∂Ω. (2)
The term ρ [1/day] denotes proliferation rate. The tumor
infiltration into the surrounding tissues is modeled by the
tensor D = {Di I}Ni=1 where I is a 3× 3 identity matrix and
Di =
{
pwiDw + pgiDg if i ∈ Ω
0 if i /∈ Ω. (3)
The terms pwi and pgi denote percentage of white and
grey matter at voxel i, while Dw and Dg stand for tu-
mor infiltration in the corresponding matter. We assume
Dw = 10Dg [mm
2/day] [28]. The skull and ventricles are
not infiltrated by the tumor cells and act as a domain boundary
with an imposed no-flux boundary condition Eq. (2), where ~n
is the outward unit normal to ∂Ω. The tumor is initialized
at voxel (icx, icy, icz) and its growth is modeled from time
t = 0 until detection time t = T [day]. The parameters
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4θu = {Dw, ρ, T, icx, icy, icz} are considered unknown and
patient-specific. The model is implemented in a 3D extension
of the multi-resolution adapted grid solver [29] with a typical
simulation time of 1-3 minutes using 2 cores. An overview of
the model Mu and its parameters is shown in Fig. 1 (II. A-C).
B. Multimodal imaging model
We consider routinely acquired T1 gadolinium enhanced
(T1Gd) and fluid attenuation inversion recovery (FLAIR)
MRI scans in combination with FET-PET maps. A stochastic
imaging model MI is designed to relate model predictions
of the tumor cell density u and the tumor observations
D = {yˆT1Gd, yˆFLAIR, yˆFET} available from the medical scans.
Here, yˆ denotes a vector of tumor observations obtained from a
certain image modality, yi is an entry in yˆ and i enumerates all
voxels in the given image. A voxel i corresponds to the same
location (ix, iy, iz) in each scan and the simulation domain Ω.
See Fig. 1 for an overview of all the imaging modalities (I.B),
corresponding tumor observations (I.C) and their relation to
tumor cell density u (II.D).
The MRI scans provide morphological information about
the visible tumor in the form of binary segmentations. The
segmentation yˆs, s ∈ {T1Gd, FLAIR} assigns a label ysi = 1
to each voxel with visible tumor and ysi = 0 otherwise. The
probability of observing a segmentation yˆs with a simulated tu-
mor cell density u is modeled by a Bernoulli distribution [28]:
P(yˆs|θ,M) =
N∏
i=1
P(ysi |θ, ui) =
N∏
i=1
α
ysi
i · (1− αi)1−y
s
i . (4)
Here αi is the probability of observing the tumor in the MRI
scan and it is assumed to be a double logistic sigmoid:
αi(ui, u
s
c) = 0.5 + 0.5 · sign(ui − usc)
(
1− e−
(ui−usc)2
σ2α
)
, (5)
where usc denotes an unknown cell density threshold below
which tumor cells are not visible in the MRI scan, while
the term σ2α represents uncertainty in u
s
c. The parameters
{θIT1Gd , θIFLAIR} = {uT1Gdc , uFLAIRc , σ2α} are assumed unknown and
patient-specific.
The FET-PET signal is proportional to tumor cell density with
an unknown constant of proportionality [13], [14]. Let yˆFET be
the normalized FET-PET signal after subtracting the patient-
specific baseline signal from healthy tissue i.e., yFETi ∈ [0, 1]
and b the corresponding constant of proportionality. We as-
sume that yFETi can be related with the modeled tumor cell
density ui as
yFETi =
1
b
ui + ε, (6)
where ε is prediction error accounting for modeling and
measurement uncertainties. Because of the noisy nature of the
PET scan, the error term is assumed to be a normal distribution
ε ∼ N (0, σ2). The probability of observing the PET signal
yˆFET with the simulated tumor cell density u is then modeled as
P(yˆFET |θ,M) =
N∏
i=1
P(yFETi |θ, ui) =
N∏
i=1
N
(
yFETi − 1
b
ui, σ
2
)
. (7)
The PET scan, acquired at 4mm resolution, is registered to
the MRI scans with 1mm resolution. To justify the product in
Eq. (7) only voxels separated by distance 4mm are used. The
parameters θIFET = {b, σ} are unknown and patient-specific.
An overview of the imaging model MI and its parameters is
shown Fig. 1 (II. D-F).
C. Parameters estimation and uncertainty propagation
The parameters θ = {θu, θI} of the model M = {Mu,MI}
where I = {IT1Gd, IFLAIR, IPET}, are assumed unknown and a
probability distribution function (PDF) is used to quantify their
plausible values. A prior PDF P(θ|M) is used to incorporate
any prior information about θ. Bayesian model calibration
updates this prior information based on the available data D.
The updated posterior PDF is computed by the Bayes theorem:
P(θ| D, M) ∝ P(D| θ,M) · P(θ|M), (8)
where P(D|θ,M) is the likelihood of observing data D from
the model M for a given value of θ. Since each of the medical
scans captures a different physiological process, the tumor
observations are assumed independent and the likelihood func-
tion can be expressed as:
P(D|θ,M) = P (yˆT1Gd|θ,M) · P (yˆFLAIR|θ,M) · P (yˆFET |θ,M) .
The prior PDF is assumed uniform with details specified in
the SM. Since an analytical expression for Eq. (8) is not
available, sampling algorithms are used to obtain samples
θ(l), l ∈ {1, · · · , S} from the posterior P(θ|D,M). We use
Transitional Markov Chain Monte Carlo (TMCMC) algorithm
[30] which iteratively constructs series of intermediate PDFs:
Pj(θ|D,M) ∼ P(D|θ,M)pj · P(θ|M), (9)
where 0 = p0 < p1 < · · · < pm = 1 and j = {1, · · · ,m} is
a generation index. The term pj controls the convergence of
the sampling procedure and is computed automatically by the
TMCMC algorithm. TMCMC method constructs a large num-
ber of independent chains that explore parameter space more
efficiently than traditional sampling methods [30] and allow
parallel execution. We use a highly parallel implementation of
the TMCMC algorithm provided by the Π4U framework [31].
The inferred parametric uncertainties are propagated through
the model M to obtain robust predictions about u given by:
P(u| D, M) =
∫
Θ
P(u| θ,M) · P(θ|D, M) dθ, (10)
or by simplified measures such as the mean µu = E[u(θ)] ≡
m1 and variance σ2u = E[u2(θ)] − m21 ≡ m2 − m21 derived
from the first two moments mk, k = 1, 2:
mk =
∫
Θ
(
u(θ|M))k · P(θ|D,M) dθ ≈ 1
S
S∑
l=1
(
u(θ(l)|M)
)k
,
where Θ is the space of all unknown parameters. The most
probable tumor cell density estimate, is given by the maximum
a posteriori (MAP) defined as uMAP = argmaxθ P(u| D, M).
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Fig. 2. Synthetic test case. Orange box: A 2D slice of the synthetic ground
truth (GT) tumor cell density (A) and corresponding image observations (B):
the normalized FET-PET signal with additive noise (red-blue color scale)
and the outlines of the T1Gd (yellow) and FLAIR (pink) binary tumor
segmentations. Blue box: Results of the Bayesian calibration with multimodal
data. The results are in close agreement with GT data. Green box: Calibration
results using only the MRI data, which do not provide enough information to
recover the tumor cell density profile correctly.
III. RESULTS
The Bayesian framework described in the previous section is
first applied to synthetic data to test sensitivity of the inference
and to show the role of multimodal image information on the
model calibration. Afterwards, clinical data are used to infer
patient-specific tumor cell densities and to design personalized
RT plans. Tumor recurrence patterns are used to compare the
proposed and standard RT plans. The software and data used
in this paper are publicly available1.
A. Sensitivity study
The model Mu is used to generate a 3D synthetic tumor
in a brain anatomy obtained from [32] using the parameters
reported in Table I. A 2D slice of the simulated ’ground-truth’
(GT) tumor cell density is shown in Fig. 2 (A). The synthetic
T1Gd and FLAIR tumor segmentations are constructed by
thresholding the GT tumor cell density at uT1Gdc = 0.7 and
uFLAIRc = 0.25. The FET-PET signal is designed by taking the
GT tumor cell density within the T1Gd and FLAIR segmen-
tations, adding Gaussian noise with zero mean and standard
deviation (std) σ, and normalizing the result. The value of σ
is chosen as average std of the FET signal from the healthy
brain tissue. The generated synthetic image observations are
shown in Fig. 2 (B).
A sensitivity study for the number of samples is performed,
indicating that 6000 samples is adequate for the model. The
manifold of the inferred probability distribution is presented
in Fig. 3 and the calibrated parameters are given in Table I.
As seen from the probability distribution manifold, tumor
observations from a single time point do not contain enough
information to infer time dependent parameters (Dw, ρ, T )
exactly, since different combinations of these parameters can
1https://github.com/JanaLipkova/GliomaSolver
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Fig. 3. The results of the Bayesian calibration for the synthetic case. Above
the diagonal: Projection of the TMCMC samples of the posterior distribution
P(θ|D,M) in 2D space of the indicated parameters. The colors indicate
likelihood values of the samples. The number in each plot shows the Pearson
correlation coefficient between the parameter pairs. The colored triangles mark
the four selected parameters used in Fig. 4. Diagonal: Marginal distributions
obtained with Gaussian kernel estimates. Boxplot whiskers demarcate the 95%
percentiles. Below the diagonal: Projected densities in 2D parameter space
constructed by 2D Gaussian kernel estimates. The black dots mark the values
used to generate the synthetic data.
(0.095, 0.022, 364)(0.16, 0.036, 218)(0.32, 0.069, 111) (0.049, 0.01, 761)
Fig. 4. Insensitivity of the tumor cell density to the speed of the growth.
Shown are slices of the tumor cell densities computed with different combi-
nations of parameters (Dw, ρ, T ) as listed at the bottom of each plot. These
correspond to the colored triangles in Fig. 3. Despite significant variation
in the parameter values, all combinations lead to very similarly-appearing
tumors. In the absence of temporal information, the time dependent parameters
are not identifiable, since the model calibration cannot distinguish between
compensating effects among the parameters that affect the dynamics. As
shown here, tumors with similar Dw/ρ and Tρ values appear very similar to
one another (here Dw/ρ ≈ 4.5, Tρ ≈ 7.7). Hence, the Bayesian calibration
identifies the probability distribution of all the plausible values.
generate the same tumor cell density as shown in Fig. 4.
The lack of identifiability of (Dw, ρ, T ) poses a challenge
for calibration approaches searching only for a single value
of θ. Instead, Bayesian calibration provides fairer estimate;
the inferred probability distribution shows a strong correla-
tion between the parameters (Dw, ρ, T ), while the high std
values imply low confidence in these parameters. On the
other hand, parameters that affect the tumor spatial pattern,
e.g. (icx, icy, icz), are identified with high accuracy, which
is reflected by their low std. The image related parameters
6TABLE I
RESULTS OF THE BAYESIAN CALIBRATION FOR THE SYNTHETIC CASE GENERATED WITH THE GROUND TRUTH (GT) VALUES. REPORTED IS MAXIMUM A
POSTERIORI (MAP), MEAN AND STANDARD DEVIATION (STD). THE UNITS ARE Dw ∼ mm2/day; ρ ∼ 1/day; T ∼ day; AND icx , icy , icz ∼ mm.
Dw ρ T icx icy icz σ b u
T1Gd
c u
FLAIR
c σ
2
α
GT 0.1300 0.0250 302.00 80.64 171.52 128.00 0.0230 0.8800 0.7000 0.2500 -
MAP 0.1226 0.0296 271.13 80.61 171.55 127.92 0.0280 0.9884 0.8440 0.4874 0.0502
mean 0.1543 0.0361 253.85 80.64 171.47 127.80 0.0294 0.9775 0.8325 0.4841 0.0505
std 0.0530 0.0125 107.59 0.1280 0.1024 0.2048 0.0022 0.0139 0.0132 0.0076 0.0004
(uT1Gdc , u
FLAIR
c , b, σ) are slightly overestimated due to the as-
sumed correlation length and the effect of the complex brain
anatomy. The role of the anatomy is discussed further in the
SM.
The inferred parametric uncertainties are propagated to obtain
robust posterior predictions about the tumor cell density shown
in Fig. 2 (C-E). Despite the large parametric uncertainties,
the MAP and mean tumor cell density estimates are almost
indistinguishable from the GT tumor. The low std values
imply that, using our Bayesian formulation, the information
contained in multimodal data is sufficient to infer tumor cell
density from single time point scans.
For comparison, if the model calibration is performed only
with the MRI data, i.e. D = {yˆT1Gd, yˆFLAIR}, the estimated
tumor cell densities shown in Fig. 2 (F-G) deviate from the
GT tumor mainly in the central part of the lesion, which
is also consistent with the regions of high std shown in
Fig. 2 (H). Nonetheless, the outlines of the predicted tumor
are similar to those of the GT tumor. This is because the
tumor morphology is mainly constrained by the MRI data,
since the FET-PET signal coincides with the baseline signal
of the healthy tissue in the regions of lower tumor infiltration.
On the other hand, the FET-PET signal constrains the tumor
cell density profile in the regions of high tumor infiltration.
This highlights the importance of integrating structural and
functional image information for the model calibration when
dealing with single time point data.
B. Patient study
A retrospective clinical study is conducted on 8 patients
diagnosed with GBM. Scans of the patients P1-P8 are shown
Fig. 5 and the details about acquisition protocols and image
processing are reported in the SM. All patients received the
standard treatment, surgery followed by combined radio- and
chemotherapy [2]. There was no visible tumor after the treat-
ment and patients were regularly monitored for recurrence.
The preoperative scans shown in Fig. 5 (A-D) are used for the
Bayesian inference. The calibrated parameters are reported in
Table 1 in the SM and the posterior, patient-specific predictions
for the tumor cell densities are shown in Fig. 5 (E-G).
These patient-specific predictions provide estimates about the
possible tumor cell migration pathways in the surrounding of
the visible tumor, constrained by the patient anatomy and the
available tumor observations. The predicted tumor infiltration
pathways can be validated by the patterns of the first detected
tumor recurrence shown in Fig. 5 (H), where the outlines of the
predicted infiltrations (blue) and recurrence tumors (pink) are
depicted. For patients P5,P7,P8 the model accurately predicts
tumor infiltration also inside the healthy-appearing collateral
hemisphere, whereas for cases P1-P4 the tumor predictions are
correctly restricted only to one hemisphere. Moreover, despite
a similar appearance of the preoperative tumors in patients
P1 and P2, the model correctly predicts more infiltrative
behaviour for the patient P1, which is consistent with the
recurrence pattern. The high confidence in the predictions is
reflected by low std shown in Fig. 5 (F).
C. Personalized radiotherapy design
The patient-specific tumor cell density predictions can
be used to design margins of the CTV and to identify
high cellularity regions that could mark areas of increased
radioresistance. The personalized RT plan can be based either
on the most probable scenario given by MAP estimate or the
worst case scenario given as a sum of the mean and std of the
tumor cell density. Since in the present study, the mean and
MAP estimates are very similar, and the std values are small,
the MAP estimates are used. An overview of the proposed
personalized RT design is shown in Fig. 1 (IV), while the
details are described in the following subsections. The tumors
recurrence patterns are used to assess the benefits of the
proposed RT plan over the standard treatment protocol. For
evaluation purposes, all recurrence scans are registered to the
preoperative anatomy. To prevent registration errors arising
from mapping the anatomy with the resection cavity to the
preoperative brain, rigid registration is used. This provides a
sufficient mapping for most cases, however it cannot capture
the post-treatment tissue displacement around the ventricles
in patients P7-P8, making the mapping less accurate in
these regions. The design of methods that provide robust
registration between pre- and post-operative brain anatomies
is still an open problem.
1) Dose distribution: An ideal CTV covers all the residual
tumor, including infiltrating tumor cells that are invisible on
the pretreatment imaging scans, while sparing healthy tissue.
We use the tumor recurrence pattern to evaluate the efficiency
(ηCTV ) of the CTV, defined here as the relative volume of the
recurrence tumor (V REC) contained within the CTV:
ηCTV =
|V REC ∩ CTV |
V REC
× 100%. (11)
Figure 5 (H) shows the FLAIR scans with the first detected
tumor recurrence outlined by the pink lines. The margin of
the administered CTV RTOG, designed by the standard RTOG
protocol with a 2 cm margin around the visible tumor, is
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Fig. 5. Results of the Bayesian calibration for patients P1-P8. Orange box: Preoperative scans showing (A) T1Gd; (B) FLAIR; (C) Tumor segmentations:
T1Gd (yellow) and FLAIR (pink); (D) FET-PET. Blue box: (E) MAP and (F) std of the inferred tumor cell densities shown in the preoperative FLAIR scans.
The CTV RTOG margin is shown as the green curves. (G) The 3D reconstructions show outlines of the MAP tumor (blue) together with tumor extent visible
on the FET-PET scans (orange) in the preoperative anatomy (white). Green box: Scans of the first detected tumor recurrence. (H) FLAIR tumor recurrence
(pink), CTV RTOG(green), and CTV MAP(blue) margins. (I) T1Gd tumor recurrence (yellow) and the dose-escalation outlines proposed by FET enhancement
(magenta) and MAP estimates (orange). (J) Multilevel dose-escalation designed by MAP estimates.
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Fig. 6. A comparison of the RT plan based on the RTOG protocol (green)
and MAP estimates (blue). (A) The overall irradiated volume V CTV and (B)
the corresponding efficiency ηCTV . The CTV MAP uses a smaller irradiation
volume while having a comparable efficiency as the CTV RTOG.
marked by the green lines in (E,F,H). The personalized CTV,
referred as CTV MAP, is constructed by thresholding the MAP
tumor cell density at u = 0.1% for all patients. (This value
was chosen so that the efficiency of the CTV MAP is comparable
to that of the CTV RTOG ). The outlines of the proposed
CTV MAP are shown as the blue isocontours in Fig. 5 (H-I).
A visual comparison of the CTVs shown in Fig. 5 (H) and
Fig. 1 (IV), and a quantitative comparison presented in Fig. 6,
show that the proposed personalized plans spare more healthy
tissue, hence reducing radiation toxicity, while maintaining
the efficiency of the standard RTOG protocol. Both plans
show reduced efficiency for patients P7-P8, mainly around the
ventricles, which may be caused by misalignment between the
preoperative and recurrence anatomies.
These preliminary results imply that the regions predicted as a
tumor-free by the model, remain tumor-free and thus the model
predictions have potential to guide personalized CTV design.
The standard or hospital-specific protocols can be updated by
the model predictions to spare brain tissue not infiltrated by
the tumor. This can lead to significant savings in the healthy
tissue, especially in the cases of large lesions or lesions close
to hemispheres separation and other anatomical constraints.
2) Dose-escalation: No dose-escalation plan for GBM pa-
tients has been yet approved by phase-III-clinical trials. Here,
we present a theoretical comparison of two escalation plans
targeting high tumor cellularity regions identified by: 1) FET-
PET enhancement as proposed in [5] and 2) MAP estimates.
We evaluate the efficiency of an escalation plan by its capabil-
ity of targeting T1Gd-enhanced tumor recurrence regions. In
these regions, the recurrent tumor has high cellularity, despite
having received the full radiation dose, suggesting tumor ra-
dioresistance. Figure 5 (I) shows the T1Gd scans with the first
detected tumor recurrence. The margins of the T1Gd-enhanced
tumor recurrence are marked by the yellow lines, while the
outlines of the dose-escalation plans designed by the FET-PET
enhancements are shown in magenta. The FET enhancements
do not fully cover the T1Gd recurrent tumor in patients P4-
P7, providing a possible explanation for why improvements
in progression-free survival have not been observed in [5]. In
comparison, the MAP estimates, calibrated by the FET-PET
signal, extend the information about the tumor cell density
in the periphery of the visible lesion. Figure 5 shows two
possible dose-escalation plans based on the inferred MAP
tumor cell density: (I) a single-level dose-escalation based
on the thresholded MAP solution with threshold u = 30%
marked by the orange lines and (J) a cascaded four-level
escalation plan constructed by thresholding the MAP tumor
cell density at u = [0.1, 25, 50, 75]%. The optimal design
of a personalized dose-escalation plan would require more
extensive studies. However, these preliminary results show that
the inferred high cellularity regions coincide with the areas
of tumor recurrence better than those suggested by the FET-
PET enhancement alone. The Bayesian inference framework
developed here thus provide a promising tool for a rational
dose-escalation design.
IV. CONCLUSION
We have demonstrated that patient-specific, data-driven
modeling can extend the capabilities of personalized RT
design for infiltrative brain lesions. We combined patient
structural and metabolic scans from a single time point with
a computational tumor growth model through a Bayesian
inference framework and predicted the tumor distribution
beyond the outlines visible in medical scans. The patient-
specific tumor estimates can be used to design personalized RT
plans, targeting shortcomings of standard RT protocols. The
software and data used in this work are publicly released2
to facilitate translation to clinical practice and to encourage
future improvements. In the future, the Bayesian framework
developed here could also be extended to predict individual
patient responses to RT by incorporating data obtained during
the course of treatment as done in [33], in which non-
spatial tumor models were used. In this way, the treatment
can be further improved by adaptively refining the RT plans
based on the predicted patient responses. Moreover, the basic
FK tumor growth model could be replaced by a Fokker-
Planck diffusion model [16], which would not increase the
number of unknown parameters or affect the computational
complexity significantly, but might provide a better description
of biological diffusion. Future work could also incorporate
more advanced models, such as [34], that account for cancer
stem cells, their progeny and nonlinear coupling between the
tumor and the neovascular network. However, it remains to
be seen whether scans acquired at a single time point would
provide enough information to calibrate the advanced models
sufficiently. If not, then simpler, well-calibrated models may
prove to be more informative. Finally, in future studies, the
computational framework developed here will be tested on
a larger patient cohort and prospective clinical trials will be
performed. In summary, the results presented here provide a
proof-of-concept that multimodal Bayesian model calibration
holds a great promise to assist the development of personalized
RT protocols.
2https://github.com/JanaLipkova/GliomaSolver
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A. Prior PDF
The parameters θ = {θu, θFT1Gd , θFFLAIR , θFFET} are assumed independent with uniform prior distribution: P (θ|M) =
∏11
j=1 P(θj |M),
where
P(θj |M) = 1
log(θmaxj )− log(θminj )
for θminj ≤ θj ≤ θmaxj , (1)
and zero otherwise. The logarithm ensures a similar order of magnitude for the prior ranges of all considered parameters, which
facilitates the sampling procedure. The prior ranges are chosen as follows: Dw ∈ [0.013, 3.8]mm2/day, ρ ∈ [0.0027, 0.19] /day
as reported in [1], T ∈ [30, Tmax + 365] day, where Tmax is the maximum time that a propagation wave with velocity
vmin = 2
√
min(Dwρ) needs to travel a distance equal to the maximum radius of the visible tumor rmax. A prior for the
initial location is taken as a cube with a side 2 rmax, centered at the tumor center of mass. The imaging model parameters
are assumed to be uT1Gdc ∈ [0.5, 0.85], uFLAIRc ∈ [0.05, 0.5], σ2α ∈ [0.05, 0.1], σ ∈ [0.015, 0.2] and b ∈ [0.5, 1.02]. The lower
bound for the scaling factor b comes from the fact the T1Gd and FET-PET scans usually do not enhance low grade gliomas,
suggesting the same lower bound for the both modalities.
B. Bayesian calibration
Table I reports the results of the Bayesian calibration for the clinical data shown in Fig. 5 in the main text.
TABLE I
RESULTS OF THE BAYESIAN CALIBRATION FOR THE PATIENT DATA SHOWN IN FIG. 5 IN THE MAIN TEXT. THE MAXIMUM A POSTERIOR (MAP)
ESTIMATES, MEANS AND STANDARD DEVIATIONS (STD) OF THE MARGINAL DISTRIBUTION ARE SHOWN FOR ALL THE PARAMETERS. THE UNITS ARE
Dw ∼ mm2/day; ρ ∼ 1/day; T ∼ day; AND icx , icy , icz ∼ mm.
Cases Dw ρ T icx icy icz σ b uT1Gdc u
FLAIR
c σ
2
α
P1: MAP 0.188 0.029 273.130 169.293 177.075 141.235 0.111 0.959 0.693 0.521 0.051
P1: mean 0.334 0.054 192.649 169.242 177.101 140.851 0.109 0.951 0.712 0.516 0.053
P1: std 0.190 0.031 107.396 0.435 0.384 0.435 0.013 0.040 0.029 0.016 0.002
P2: MAP 0.060 0.024 337.582 108.186 158.182 173.926 0.160 0.846 0.559 0.436 0.051
P2: mean 0.090 0.036 407.101 108.262 157.978 173.850 0.161 0.859 0.577 0.448 0.053
P2: std 0.086 0.034 257.528 0.384 0.358 0.512 0.014 0.055 0.027 0.016 0.003
P3: MAP 0.846 0.010 1094.225 112.998 155.520 117.632 0.218 0.925 0.614 0.347 0.056
P3: mean 0.667 0.008 1468.721 111.821 154.035 118.298 0.214 0.884 0.627 0.352 0.061
P3: std 0.133 0.002 299.056 2.611 3.046 2.074 0.004 0.029 0.011 0.013 0.003
P4: MAP 0.223 0.010 848.498 163.405 162.944 183.347 0.149 1.011 0.796 0.416 0.050
P4: mean 0.227 0.010 1015.395 163.533 162.918 183.245 0.142 1.009 0.793 0.417 0.051
P4: std 0.167 0.007 403.933 0.333 0.410 0.307 0.010 0.009 0.005 0.007 0.000
P5: MAP 2.447 0.107 93.278 117.453 110.541 141.517 0.219 1.020 0.601 0.374 0.051
P5: mean 2.285 0.101 101.387 117.376 110.310 141.312 0.205 1.005 0.609 0.368 0.051
P5: std 0.312 0.014 17.692 0.691 0.486 0.333 0.008 0.013 0.006 0.008 0.001
P6: MAP 0.440 0.029 406.237 127.053 167.450 167.731 0.193 0.937 0.614 0.369 0.052
P6: mean 0.869 0.053 311.425 124.442 166.093 166.912 0.190 0.949 0.642 0.379 0.053
P6: std 0.557 0.033 262.315 1.024 0.947 0.870 0.014 0.040 0.021 0.010 0.002
P7: MAP 0.196 0.007 1580.353 162.867 98.509 121.088 0.218 0.837 0.604 0.362 0.052
P7: mean 0.282 0.010 1204.162 163.354 96.640 123.110 0.213 0.807 0.605 0.359 0.052
P7: std 0.079 0.003 340.776 0.486 1.408 1.024 0.004 0.020 0.004 0.009 0.001
P8: MAP 0.484 0.025 391.577 166.528 119.270 160.154 0.131 0.866 0.602 0.355 0.050
P8: mean 0.689 0.034 353.465 166.093 119.219 160.410 0.130 0.845 0.605 0.355 0.051
P8: std 0.399 0.020 190.028 0.256 0.205 0.256 0.003 0.017 0.003 0.005 0.001
Copyright (c) 2019 IEEE. Personal use of this material is permitted. However, permission to use this material for any other purposes must be obtained from
the IEEE by sending a request to pubs-permissions@ieee.org.
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2C. Effect of the brain anatomy on the tumor cell density
The patient-specific anatomical restrictions and anisotropic tumor growth result in tumor cell densities that are not constant
across the borders of the T1Gd and FLAIR tumor segmentations. Figure 1 (A) shows the distribution of the inferred tumor cell
densities across the tumor borders visible in T1Gd and FLAIR scans. The distributions vary significantly along the borders
and among the patients. This is not surprising, since in the regions of anatomical restrictions, the outlines of the T1Gd and
FLAIR tumor segmentations coincide. The effect of the anatomical restrictions can be alleviated by considering the tumor cell
density only at the tumor segmentation outlines far from the ventricles and skull. In this case the inferred tumor cell densities
vary less and are also more consistent among the patients as shown in Fig. 1 (B). This implies the importance of considering
the imaging parameters patient-specific, especially when dealing with complex anatomies such as the brain.
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Fig. 1. The effect of the brain anatomy on the tumor cell density. A) Distribution of the inferred tumor cell densities at the border of the T1Gd (green)
and FLAIR (purple) tumor segmentations represented by box plots. B) Distribution of the tumor cell densities at segmentation borders far from anatomical
restrictions. Boxplot whiskers demarcate the 95% percentiles.
D. Acquisition protocol
The MRI scans were conducted with 3T mMR Biograph scanner (Siemens Medical Solutions, Germany). FET-PET scans
were acquired on a SIEMENS Biograph 64 PET/CT scanner. For standardized metabolic conditions, patients were asked to
fast for a minimum of 6h before the PET scan. Intravenous administration of 190 MBq of FET was performed, and low-dose
CT (2426 mAs, 120 kV) for attenuation correction was acquired. Ten-minute PET acquisitions were performed 30 to 40 min
post-injection. PET data were reconstructed by filtered back-projection using a Hann filter with corrections for attenuation,
scatter, and radioactive decay. All patients provided informed written consent. The study was approved by the ethics committee
of the TU Munich and carried out in accordance with the approved guidelines.
E. Image processing
The scans of each patient were registered to preoperative T1Gd scans using affine ANTs registration [2]. The white matter,
gray matter, and cerebrospinal fluid were segmented from T1 MRI scan using an atlas-based segmentation approach1. In this
way, the brain atlas is deformed to reach a spatial consistency with the visible brain tissue of the patient, while the tissue
underneath the tumor is described by the anatomy of the deformed atlas. The tumors were segmented with a generative
Expectation-Maximization algorithm [3]. All segmentations were manually inspected and corrected if needed.
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